Global Vaccine Action Plan 2011 - 2020

World Health Assembly

The Global Vaccine Action Plan (GVAP) ― endorsed by the 194 Member States of the World Health Assembly in May 2012 ― is a framework to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

GVAP aims to strengthen routine immunization to meet vaccination coverage targets; accelerate control of vaccine-preventable diseases with polio eradication as the first milestone; introduce new and improved vaccines and spur research and development for the next generation of vaccines and technologies.

April 24, 2016
Year of publication
2012
Resource types
Tools
Tags
World Immunization Week, immunization, child immunization, immunization services, Ebola vaccine, malaria vaccine, vaccinations, HPV vaccine, vaccination coverage

Similar Resources

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

This is an updated introductory two-page document that defines AIDS vaccines and reviews key developments in the field.

What have scientists learned that helped inform the design of this pivotal AIDS vaccine study in South Africa?

The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection.

The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of the HIV-1 cure field.

A quick, colorful and comprehensive overview of HIV vaccine research. Four pages, five top-line updates, this is a speedy read, designed to give a sense of the momentum and major issues coming up in the year to come.

The HIV pandemic continues to impose enormous morbidity, mortality, and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis.

Integrated, multidisciplinary responses are increasingly critical from economic, political and health systems perspectives; piecemeal approaches leave too many gaps in the elements left unaddressed.

Data on carcinogenicity of human papillomavirus (HPV) types in the anus are needed to inform anal cancer prevention through vaccination and screening. This is particularly the case for people infected with HIV, who are at an increased risk of anal cancer.